Rational Exuberance

David Nelson, CFA CMT  |

Even before Pfizer's historic announcement that its COVID-19 vaccine trial was showing 90% efficacy, the S&P 500 was on track to break out above important resistance. Stocks have been held hostage trapped in a 350-point S&P trading range defined by the all-time September 2nd high and where 2020 started. In a near manic depressive state, investors have been caught in a tug of war with rising COVID-19 cases, increased shutdowns and political unrest on one side and falling unemployment, better economic data and strong earnings on the other.

Click to enlarge

The Pfizer news trashes the current investor playbook of hiding in stay-at-home beneficiaries. The epicenter stocks exploded higher including airlines, cruise stocks and even REITs like SL Green +37% on the day. Energy stocks were up between +10 & +30% with the broad sector +14%.

Of course the capital to buy these names had to come from somewhere, and the obvious source of funds was the stay-at-home trade including Netflix, Docusign, Zoom and Peloton.

Rational or Irrational?

Click to enlarge

Subscribe to get our Daily Fix delivered to your inbox 5 days a week

The knee jerk reaction of course is to assume Monday's rotation was overdone and, in the short run, that could easily be true... but consider the following: Coming into the week the spread between the Nasdaq 100 and the Equal Weight S&P 500 ETF was close to 40%. Most of the heavy lifting has come from a handful of mega cap growth stocks, many of which actually benefited from the shutdown.

Monday's close of the Nasdaq should give Growth Bulls pause. The Invesco QQQ Trust put in an outside day to the downside on higher than normal volume.

Click to enlarge

Reversion to the mean is a powerful force and if the COVID-19 vaccine candidate continues to show promise or if, as some say, other vaccines follow, the irrational quickly becomes rational in that context.

Growth performs best when there isn't any. It makes perfect sense for investors to move down the valuation curve into obvious beneficiaries of a vaccine including transportation, industrials and close proximity businesses like restaurants. If economic activity continues to improve, banks will be the beneficiary of a steepening yield curve. No, the growth trade isn't dead, but you may have to make some room for those previously left behind.

Don't make the mistake in thinking that a vaccine will save all.

COVID-19 accelerated a lot of trends already in place. The move to online life had been well established, and retailers like Target, Walmart and others that went to great lengths to revamp their business models will succeed long term. Those that didn't will enjoy dead cat bounces that may last for a while but ultimately will succumb to economic trends once the euphoria subsides.

*At the time of this article some funds managed by David were long Walmart, Invesco S&P 500 Equal Weight ETF and Energy Select Sector SPDR Fund.


David Nelson is Chief Strategist for Belpointe Asset Management.


Equities Contributor: David Nelson, CFA CMT

Source: Equities News

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not necessarily represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer.

Trending Articles

Kroger App Causes Customer Frustration, Hurts Brand: Jeff Kagan
The Shipping Container Was the Most Important Invention of the 20th Century
Currencies and the Global Expansion of Money Supply
Commodities Post Strongest Gains in Over a Decade

Market Movers

Sponsored Financial Content